Recruiting
Phase 1 / Phase 2
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
About this study
This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.
- Condition
- Small Cell Lung Cancer, Neuroendocrine Carcinoma
- Tested
- ZG006, ZG005
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Who can join
- Age
- 18 to 70 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 8
- Minimum age: 18 years
- Maximum age: 70 years
- Study condition: Small Cell Lung Cancer, Neuroendocrine Carcinoma
- Fully understand the study and voluntarily sign the informed consent form.
- Male or female 18-70 years of age.
- Participants with advanced small cell lung cancer or neuroendocrine carcinoma confirmed by histopathology or cytology.
- Eastern Cooperative Oncology Group (ECOG) 0 to 1.
- Life expectancy \> 3 months.
Exclusion 1
- The investigator believes that the subject has other reasons that make them unsuitable for participation in this study.
Where
1 site, 1 recruiting
Sun Yat-sen University Cancer Center
Guanzhou, Guangdong, China
Contact
-
Hewen Yin
+86-0512-57309965 yinhw@zelgen.com
Potential match only. Final eligibility is determined by the study team.